Dendritic cells (DC) 
Introduction
Dendritic cells (DC) are the most potent professional antigen-presenting cells (APC) with exquisite capacity to interact with naive T cells to initiate primary immune responses.
1 DC, loaded with antigen ex vivo, have been shown to be able to induce potent anti-tumor and antiviral immune responses in vitro and in vivo. 2, 3 The generation of clinically relevant immune responses by antigenloaded DC could be demonstrated for certain types of human malignancies. 4, 5 Recently, it has also been demonstrated that DC, regardless of the route of injection, can induce antigen-specific T cell immunity in cancer patients. 6 DC are derived from bone marrow progenitors and circulated in the blood as immature precursors prior to migration into peripheral tissues. Within different tissues, DC differentiate and become active in the taking up and processing of antigens, and their subsequent presentation on the cell surface linked to major histocompatibility (MHC) molecules. Upon appropriate stimulation, DC undergo further maturation and presumably migrate to secondary lymphoid tissues where they present antigen to T cells and induce an immune response. genitors, the wide application of DC for clinical immunotherapy is still difficult and far from ideal. Recently, it has been reported that administration of the novel human hematopoietic growth factor, FLT-3 ligand (hFlt-3L), into mice has a profound effect upon the generation of functional mature DC in multiple organs. 8 Although no tumor-specific immunity could be demonstrated, it has been recently reported that following treatment with human Flt-3L, there is a markedly recruitment of DC into the tumor site. 9, 10 The ability to generate DC in vivo following the treatment with hFlt-3L offers many advantages for the design of cellular immunotherapy regimes. Firstly, there is the potential that multiple and distinct DC subsets with differentially immune regulatory functions could be generated and this could be of great importance in eliciting optimal immune responses. This is especially important given that there is growing evidence to demonstrate that DC could be further sub-classified into myeloid-and lymphoid-derived subsets. [11] [12] [13] In addition, the expansion of DC in vivo in lymphoid and non-lymphoid organs would greatly increase the chance of interactions with antigen-specific precursor T cells.
Recently, we have demonstrated that the introduction of the recombinant gene encoding the hFlt-3L into mice could result in the expansion of the DC population in vivo. 14 In this report, we have introduced the hFlt-3L gene via naked DNA-based immunization in combination with the muc-1 tumor peptide to immunize animals. We demonstrated that the population of DC expanded following stimulation with the hFlt-3L gene in vivo is functional and they are able to generate an efficient peptide-specific cellular response. The strategy described here enables a more efficient approach to generate antigenspecific CTL immunity in vivo and could potentially be employed in developing efficient protocols for antigenspecific immunotherapy of human malignancies.
Results
Muc-1 pulsed DC could act as APC to antigen-specific CTL Bone marrow (BM) cells were harvested from mice and cultured in the presence of GM-CSF and IL-4 for 10 days to generate DC. The DC obtained following culturing in vitro were analyzed by FACS. The phenotypes of these BM-DC, as shown in Figure 1 , were comparable to that published for mature DC. 15 To determine if the DC generated could function as APC, muc-1 peptide having the sequence, PDTRPAPGSTAPPAHGVTSAPDTRPAPGST, was synthesized. The flu peptide having the sequence IASNENMETMESSTLE was also synthesized and acted as a control peptide. To generate muc-1-specific CTL, three immunization protocols, as described in Materials and methods, were followed. Two types of target cells were employed in assessing the CTL activities: blast cells pulsed with the muc-1 peptide and transfected muc-1 + RMA lymphoma cells (RMA-muc-1). In contrast to mice immunized with the muc-1 peptide that generate high level of anti-muc-1 antibody (Figure 2 ), mice immunized with muc-1 pulsed BM-DC cells displayed high levels of primary and secondary muc-1-specific CTL (Figure 3a and b) . The highest level of muc-1-specific CTL activities were detected in mice immunized twice with muc-1 pulsed BM-DC and followed by a secondary in vitro stimulation with the muc-1 peptide (Figure 3b) . No anti-muc-1 CTL responses could be detected in mice immunized twice with the muc-1 peptide (Figure 3a and b). The generation of high muc-1-specific CTL activities was correlated with the high level of CTLp detected in mice immunized with muc-1-pulsed BM-DC (Table 1) . As shown in Table 1 , the average CTLp frequency was 1/583 121 for mice that were immunized with the muc-1 peptide alone. The CTLp frequency was greatly enhanced in mice that were firstly immunized with muc-1 pulsed BM-DC and then with the muc-1 peptide (average CTLp of 1/47 329). Mice given two immunizations with muc-1 pulsed BM-DC gave the highest average CTLp frequency of 1/32 122. The generation of muc-1-specific CTL activities was also correlated with the production of IL-2 and IFN-␥ in culture supernatants of spleen cells from mice immunized with muc-1-pulsed BM-DC (Figure 4 ). In comparison, culture supernatants After confirming that muc-1-pulsed BM-DC could generate efficient muc-1-specific CTL, we explore the possibility of inducing the expansion of DC in vivo via immunization with the pNGVL3-hFLex plasmid DNA.
Induction of CD11c
+ DC via in vivo immunization with pNGVL3-hFLex plasmid DNA To determine the optimal time to administer the muc-1 peptide in vivo to achieve maximum CTL responses, we have studied the effect of the pNGVL3-hFLex plasmid DNA on the expansion of DC in vivo. The kinetics of the induction of DC expansion in vivo was quantitated using FACS to determine the percentages of DC in the spleen, lymph nodes, thymus, blood and the peritoneal cavity of immunized mice at different time-points following gene delivery by the hydrodynamic-based method. It has previously been demonstrated that the level of gene expression obtained following the hydrodynamic-based DNA injection protocol reached a saturation level at approximately 5-10 g plasmid DNA and further increase of the concentration of DNA would not result in further transgene expression. 16 We have also previously reported that following gene delivery of the pNGVL3-hFLex plasmid DNA, a peak serum level of 20-30 g/ml Flt-3L was detected 24 h after injection.
14 Flt-3L level was progressively decreased and maintained above or around 1 g/ml until day 6.
14 There was no noticeable toxicity resulting of the high level of Flt-3L in mouse serum. A single injection of the pNGVL3-hFLex plasmid DNA could lead to 15-18% of detectable CD11c + DC in various lymphoid and non-lymphoid organs between days 7 and 10 following immunization. However, there is steady decrease in CD11c + DC at day 10 following immunization and the number of CD11c + DC returned to the basal level by day 20 ( Figure 5 ). No corresponding expansion of T and B cells could be detected. The expansion of DC in vivo resulted in multiple organomegaly including that of the spleen and lymph nodes of the immunized mice. The number of DC started to reduce from day 12 onwards and by day 20 it reached a level comparable to that of the non-immunized mice ( Figure 5 ). This may suggest the presence of a negative feedback regulatory mechanism in operation. A second injection of the pNGVL3-hFLex plasmid DNA could again lead to the expansion of DC thus indicating that no tolerance mechanism is induced ( Figure 5 ). The percentages of DC attained were comparable to that of the first injection ( Figure 5 ). The parental plasmid pNGVL3 has no effect on DC ( Figure 5 ). Cell surface phenotypes of bone marrow-derived DC (BM-DC) and splenic DC induced by the pNGVL3-hFLex plasmid DNA (hFlex-DC) were identical After establishing the optimal kinetics for the induction of DC in vivo via injection of the pNGVL3-hFLex plasmid DNA, the phenotypes of the splenic hFlex-DC and BM-DC was studied. Splenic hFlex-DC were isolated from the spleen of mice at day 7 following the immunization with pNGVL3-hFLex plasmid DNA. Both BM-DC and hFlex-DC exhibited a high level of the co-stimulatory molecules CD80 and CD86 ( Figure 6 ). However, injection of the pNGVL3-hFLex plasmid DNA resulted in the generation of lymphoid-derived DC (CD8␣ + ), as well as the myeloidderived DC ( Figure 6 and Table 2 ). Table 2 summarized Table 1 CTLp the characteristics of BM-DC and hFlex-DC collected at days 7 and 10.
hFlex-DC are immune competent
To study whether the hFlex-DC were functional and able to act as APC in vitro, CD11c + DC were purified from splenocytes at days 7 and 10 following the injection of (Table 1) . From these results, it appeared that the BM-DC might be more efficient in functioning as APC in vitro than hFlex-DC, the hFlex-DC are nevertheless immune competent and are able to uptake, process and present antigens to generate potent immune responses.
hFlex-DC are capable of processing the muc-1 antigenic peptide in vivo to generate potent anti-muc-1 CTL responses
After demonstrating that the hFlex-DC are immune competent and are able to present antigens in vitro, we then
Figure 7 hFlex-DC are functionally competent. (a) Alloreactivity. hFlex-DC were capable of inducing allo-T cells reactivities. Purified ␥-irradiated BM-DC or splenic hFlex-DC were co-cultured with allo-T cells and the reactivities measured as described in Materials and methods. (b) MUC-1 specific CTL. MUC-1 pulsed hFlex-DC were able to induce muc-1 specific CTL. BM-DC or hFlex-DC purified after immunization with pNGVL3-hFLex plasmid DNA for 7 and 10 days were pulsed with the muc-1 peptide in vitro and then inoculated into mice. Ten days later, spleen cells were collected and tested for secondary CTL activities. (c and d) Production of cytokines. Spleen cells harvested after immunization with the muc-1 pulsed BM-DC and hFlex-DC were stimulated in vitro with muc-1 peptide and the respective culture supernatant on days 3 or 6 was collected for IFN-␥ (c) and IL-2 (d) assay.
Gene Therapy investigated if the hFlex-DC generated in vivo following the injection of pNGVL3-hFLex plasmid DNA could act directly as APC to present antigens in situ. Different amounts of the muc-1 antigenic peptides were employed for the immunization and different routes of administration of the muc-1 peptides were examined. Seven days following the injection of the pNGVL3-hFLex plasmid DNA, 60 g of the muc-1 peptide was injected directly into the spleens of mice (intrasplenic injection). After 10 additional days, the immunized mice were killed and the spleen cells harvested for CTL assays. Significant muc-1-specific proliferative responses ( Figure  8a ) and anti-muc-1-specific secondary CTL responses (Figure 8b ) could be demonstrated in mice primed with the pNGVL3-hFLex plasmid DNA, but not with the control parental vector pNGVL3 (Figure 8 ). No anti-muc-1 antibody could be detected in this group of immunized mice (data not shown). These results suggest that the in vivo expansion of DC following injection of the pNGVL3-hFLex plasmid DNA into the spleens of the recipient mice mainly activated the cellular pathway of the immune system.
When 60 g of the muc-1 peptides were given via either intraperitoneally or intravenously following the injection of pNGVL3-hFLex plasmid DNA, no muc-1-specific CTL response could be generated (Figure 8b ). However, when 300 g of the muc-1 peptide were given intravenously following injection of the pNGVL3-hFLex plasmid DNA, significant muc-1-specific secondary CTL responses could be detected (Figure 8b ). Following this immunization protocol with high concentration of the muc-1 peptide, the production of anti-muc-1-specific antibodies in the recipient mice could also be demonstrated ( Figure 9 ). The summary of the various immune responses elicited following injection of the pNGVL3-hFLex plasmid DNA is listed in Table 3 .
Anti-tumor response demonstrated in mice following the in vivo stimulation with the pNGVL3-hFLex plasmid DNA and muc-1 peptide
The ability of mice immunized with pNGVL3-hFLex plasmid DNA and muc-1 peptide to induce effector CTLs in vitro suggested that this vaccination would also provide anti-tumor protection in vivo. This was tested in an experimental tumor model, whereby mice were first immunized with pNGVL3-hFLex plasmid DNA and muc-1 peptide and challenged 10 days later with a lethal s.c. dose of 5 × 10 5 RMA-muc-1 or RMA tumor cells (Figure 10 ). Mice pre-immunized with both pNGVL3-hFLex plasmid DNA and muc-1 peptide gave a marked delay in tumor progression when challenged with the RMA-muc-1 tumor cells (Figure 10a ). In comparison, RMA-muc-1 tumor cells grew aggressively in control mice that were pre-treated either with pNGVL3-hFLex plasmid DNA alone or muc-1 peptide alone in mice and implanted with RMA-muc-1 (Figure 10a ). After approximately 3 weeks, the mice in the control group had to be killed due to excessive tumor growth. The parental RMA tumor cells grew aggressively in both primed and unprimed mice (Figure 10b ).
Discussion
The ability to generate a potent antigen-specific cellular immune response depends on many factors including the nature of the antigen and the route of immunization. DC express high levels of the MHC molecules and immune co-stimulatory accessory molecules, as well as the secretion of many potent T cell-activating cytokines that are critical for the generation of an effective immune response. DC are professional APC which specialize in capturing and presenting antigens to stimulate T-dependent immunity. DC are able to process antigens into immunogenic fragments that bind to the MHC molecules to trigger T cell responses. In addition, DC home to most of the T cell areas within lymphoid organs where they are in close contact with T cells. 7 The identification of TAA recognized by CTL has improved the prospect for cancer immunotherapy. One family of TAA that can induce a specific immune response is the mucin molecules. Mucin molecules, such as muc-1, are large transmembrane glycoproteins that have been recognized as potential targets for immunotherapy in human adenocarcinomas. Several lines of evidence have demonstrated that muc-1 can act as an immuno-dominant epitope to generate T and B cell immunity. In cancers of the gastrointestinal tract, ovary, breast, pancreas, kidney and lung, muc-1 was found to be hypo-glycosylated and showed a 10-to 40-fold increase in expression. 17 The under-glycosylation of muc-1 exposes a highly immunogenic peptide epitope within a variable number of tandem repeats (VNTR).
In this report, we have designed a 30-mer synthetic muc-1 peptide containing the amino acid sequence of the tandem repeats and were able to demonstrate initially that BM-DC derived in vitro could elicit muc-1-specific CTL, when pulsed with muc-1 peptide (Figure 3 ). This is likely to be of the Th1 immune response as high level of IL-2, IFN-␥ and low level of IL-10 were detected ( Figure  4 ). This is in marked contrast to the generation of muc-1 antibody response when the muc-1 peptide is employed directly for immunization (Figure 2) . Accumulating evi- dence also suggests that the types of cytokines secreted during the early stages of primary responses are crucial factors that determine the outcome of the immune responses and the types of T cells generated. 18 DC are able to produce and secrete IL-12, a cytokine that can induce naive CD4 + Th0 cells into IFN-␥-secreting Th1 lymphocytes. 19 The differentiation of Th0 to Th1 cells could explain the ability for mice to generate CTL responses following immunization with muc-1-pulsed DC. Interestingly, the production of high titer of IL-10 in mice immunized with muc-1 peptide that could potentially induce Th2 cells 20 correlated with the production of antibody (Figure 2 ). This agrees with other reports 21, 22 and suggests that there is only a low number of APC, Gene Therapy including DC, that are available to trigger an efficient cellular response in vivo.
Previously, it has been reported that the Flt-3L protein could induce the expansion of DC in vivo. Therefore, the administration of 10 g/mouse/day of the hFlt-3L protein for 9 days consecutively would result in 15-20% detectable DC in vivo. 4 In the present report, we have studied in a murine model, the generation of potent peptide-specific CTL responses via a single immunization with the pNGVL-3-hFLex plasmid DNA and the immunogenic peptide muc-1. Our approach is based on the assumption that the expansion of DC in situ will enhance APC and would subsequently increase the ability of the immunized host's cellular immune responses to exogenous peptides. The ability to expand DC in situ circumvents many practical problems currently associated with the culturing of DC from BM progenitors in vitro. The generation of BM-DC needs to employ many expensive cytokines. Moreover, the culturing of DC in vitro might encounter additional problems such as contamination and the possible changes in the physiological properties of DC. For example, GM-CSF is commonly employed for the culturing DC in vitro. 15 However, it was reported that GM-CSF-treated mice did not generate a significant increase in the number of DC in the lymphoid and non-lymphoid compartments. 23 This evidence suggests that perhaps other additional growth factors might also be important for the generation of DC in vivo and the DC obtained through culturing in vitro could potentially be somewhat different from that generated in vivo. Therefore, the ability to expand DC in vivo following the injection of the pNGVL3-hFLex plasmid DNA as demonstrated in this report offers the additional advantages including the generation of potentially multiple DC subsets that might be of great importance in eliciting optimal antigen-specific responses. 24 This is especially important given that although the exact lineage derivation of DC remains controversial, there is growing evidence to suggest that DC could be subdivided into myeloid-derived and lymphoid-derived subsets. 25, 26 Each subset might potentially play a different role in the regulation and generation of immune responses. In addition, the in vivo expansion of DC occurs in both lymphoid and non-lymphoid organs and thus would enhance the chances of allowing its interaction with T cells.
Several attempts to employ the soluble form of the mucin molecules such as mucin glycoproteins, recombinant mucin molecules, or synthetic mucin peptides to generate cellular responses had failed. The introduction of the muc-1 cDNA into DC or EBV-transformed B cells with various viral constructs 27, 28 and the utilization of muc-1 fusion protein to induce specific muc-1 immune responses 29 have also been reported. In these reports, only antibody response could be generated, but not T cell response. In addition, a phase I trial employing a muc-1 synthetic peptide vaccine of 105 amino acids failed to demonstrate an anti-tumor response. 30 The phase I clinical vaccine trial employing the muc-1-mannan fusion protein generated strong antibody responses, but poor cellular responses. 31 The ability to demonstrate the generation of muc-1-specific CTL with our approach is of great interest as this shows the potential of employing the VNTR region as immunogen to stimulate T and B cell cellular responses in humans. The single injection of the pNGVL3-hFLex plasmid DNA to expand DC in vivo would greatly simplify the procedures of potential immunotherapeutic protocols. The CD11c + DC when purified by MACS magnetic separation from the spleens of mice at days 7 and 10 following immunization with the pNGVL3-hFLex plasmid DNA were fully functional and could act as APC.
In the present study, we could only detect the production of anti-muc-1 antibodies, but not CTL response if mice were immunized only with the synthetic 30-mer muc-1 peptide (Figure 2) . However, when the same synthetic 30-mer muc-1 peptide was presented in the context of BM-DC or hFlex-DC, potent anti-muc-1 CTL responses could be detected (Figure 7) . Apparently, DC pulsed with peptides such as muc-1 were able to divert the outcome of the immune response from a humoral response to that of a potent cellular immune response and to effect the retardation of tumor growth (Figure 10 ). Mice that were immunized with two doses of muc-1-pulsed DC had slightly higher CTLp frequency (1/32 122) in comparison with mice that were firstly immunized with muc-1-pulsed DC and then received a second immunization with the muc-1 peptide (1/47 329). Moreover, mice that were immunized with two doses of muc-1-pulsed hFlex-DC gave a CTLp frequency of 1/44 637. All of these CTLp frequencies were much higher than those obtained for mice immunized twice with the muc-1 peptide (1/583 121). Interestingly, it was observed that muc-1/hFlex-DC induced a relatively lower level of CTL responses, lower level of IFN-␥ and IL-2 in comparison with that of muc-1/BM-DC. The exact explanation for these quantitative differences in the level of responses is currently unknown. More importantly, the CTL response could confer tumor protection in mice (Figure 10 ). The immunogenicity of DC would undoubtedly depend on many factors. 32 It has also been shown previously that the in vitro culture conditions employed to generate BM-DC could play a role in determining their subsequent immunogenicity in vivo. 33 The ability to generate immune-competent DC in vivo via a single immunization with the pNGVL3-hFLex plasmid DNA and to generate a subsequent potent peptide-specific CTL response when coupled with immunogenic peptides such as muc-1, will undoubtedly allow the design of alternative approaches for the cellular immunotherapy of cancer.
Materials and methods

Animals and cell lines
Female C57BL/6 mice were purchased from the Animal Laboratory Unit of the National University of Singapore and were used at 8-12 weeks of age. The RMA (H-2 b ) lymphoma parental cell line and transfected muc-1 + RMA cells were gifts of Dr B Acres (Transgene, Strasbourg, France).
Peptides
The synthetic 30-mer muc-1 peptide, employed in this study, has the amino acid sequence PDTRPAPGSTAP-PAHGVTSAPDTRPAPGST and falls within the VNTR region of the muc-1 molecule. 34, 35 A second peptide, derived from NP 365-380 of the human influenza virus and has the amino acid sequence IASNENMETMESSTLE, Gene Therapy was employed as a control. 36 The peptides were synthesized and obtained from Mimotopes, Clayton, Victoria, Australia. It was purified by HPLC and found to be >95% in purity.
Plasmid DNA The pNGVL3-hFLex plasmid contains the extracellular domain (secreted form) of the human Flt-3L gene was obtained from the Vector Core Laboratory at the University of Michigan (Ann Arbor, MI, USA) and has been described previously. 37 Preparation of bone marrow-derived DC DC were prepared from bone marrow cells essentially according to the procedures described by Inaba et al. 15 Briefly, bone marrow was flushed from the tibia and femur of C57BL/6 mice and depleted of erythrocytes with Tris-ammonium lysis buffer. The remaining cells were then cultured using the RPMI 1640 medium (Life Technologies, Grand Island, NY, USA) supplemented with 100 g/ml streptomycin (Life Technologies), 0.1 mM non-essential amino acids (Life Technologies), 2 mM glutamine, 1 mM sodium pyruvate, 10% heat inactivated fetal bovine serum (HyClone Laboratories, UT, USA), 50 M 2ME, 1000 U/ml GM-CSF (BD Pharmingen, San Diego, CA, USA) and 500 U/ml IL-4 (BD Pharmingen). At day 3 of culture, the non-adherent cells were gently removed and fresh medium with cytokines was added. On day 10, non-adherent and loosely adherent cells were harvested. DC were then purified from the cells harvested via CD11c
+ micromagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). The purified DC were then stained for the following cell surface markers: I-A b , CD11c, CD80 and CD86 (BD Pharmingen).
Preparation of muc-1 pulsed DC
Purified DC were resuspended in complete culture medium containing 60 g/ml of the muc-1 peptide. After incubating for 2 h at 37°C, cells were washed five times with RPMI 1640 alone to remove the FCS before injection into mice.
Immunization of mice
Three different immunization protocols were employed. Three separate groups of naive C57BL/6 mice were primed separately according to the following protocols. For the first group of mice, they were immunized twice with 60 g of the muc-1 peptide each time and at 10-day intervals. The second group of mice was primed firstly with 1 × 10 6 muc-1-pulsed DC and followed by a second immunization with 60 g of the muc-1 peptide 10 days later. The third group of mice was immunized twice with 1 × 10 6 muc-1-pulsed DC each time and at 10-day intervals. Spleen cells were prepared from these immunized mice 10 days after the second immunization and employed for the proliferation and/or CTL assays.
Gene delivery
In vivo delivery of plasmid DNA via hydrodynamicbased tail vein injection or direct injection of naked DNA into spleens of mice has been described previously. 16, 38 Briefly, 10 g of DNA was diluted in 1.5-2 ml of sterilized 0.9% NaCl solution and injected into spleen or tail vein over 10 s using a 271/2 g needle.
Purification of hFlex-DC
Spleen cells were prepared from mice immunized with the pNGVL3-hFLex plasmid DNA. DC were then purified from the cells harvested via CD11c
+ micromagnetic beads (Miltenyi Biotec). The purified hFlex-DC were then stained for the following cell surface markers: I-A b , CD11c, CD80, and CD86 (BD Pharmingen). Cs generated-gamma radiation (Nordion, Kanata, Canada) were added to achieve various responder:DC stimulator ratios. Control groups included: irradiated DC preparations cultured without responder cells; responder cells cultured without DC preparations. Each group was cultured in triplicate. The proliferative response was measured after 4 days of incubation as described above.
Proliferation assay
CTL assay
Spleen cells were prepared from the immunized mice. The spleen cells were either employed directly as effector cells in 51 Cr-release assay or were further stimulated in vitro with 10 g/ml muc-1 peptide in U-bottom microtiter plates for 6 days before being harvested as effector cells for the 51 Cr-release assay.
51
Cr-labeled target cells (10 4 cells) and effector spleen cells at various ratios were resuspended in culture medium and added into the 96-well, U-bottom plates. The plates were centrifuged at 100 g for 3 min to initiate cell contact and then incubated for 6 h at 37°C in 10% CO 2 . After incubation, the supernatants were collected and the amount of radioactivity quantified.
Preparation of target cells
Spleen cells (2 × 10 6 ) were cultured with 5 g/ml Concavalin A (ConA) (Sigma Chemical, St Louis, MO, USA) in 24-well plates for 2 days at 37°C in 10% CO 2 . The blast cells obtained following stimulation were then incubated for 12 h either with 60 g/ml of the muc-1 peptide or the flu peptide. The peptide-pulsed blast cells were then labeled by incubating with 100 Ci of Na 2
51
CrO 4 (Amersham Life Science) for 60 min at 37°C, followed by extensive washing. These labeled peptide-pulsed blast spleen cells were then employed as target cells for the 51 Cr-release assays. Other target cells employed in the 51 Cr-release assays included the parental lymphoma cell line RMA and one of its muc-1-transfected clones.
Determination of CTLp frequency
For CTLp determination, mice were primed twice either with muc-1 pulsed BM-DC or muc-1 pulsed hFlex-DC. Ten days after the second priming, the spleens were harvested for CTLp determination.
For each of the spleen cell preparations for the determination of the CTLp frequencies, a minimum of 32 replicates including at least six responder doses (ranging from 1 × 10 3 to 5 × 10 5 responder cells per well) were cultured in U-bottom microtiter plates. Irradiated C57BL/6 spleen cells (5 × 10 5 cells) were added as APC, in RPMI 1640 complete medium supplemented with 10 g/ml synthetic muc-1 peptide and 2% culture supernatant obtained from Concavalin A-stimulated rat spleen cells (ConA sup). After culturing for 6 days, each microculture was assayed for cytotoxicity by replacing 0.1 ml of the culture media with 0. CTLp frequencies were then determined as the inverse of the responder cell dose required for the generation of 37% wells that were negative for CTL activities.
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Enzyme-linked immunosorbent (ELISA) assay
To detect the presence of anti-muc-1 antibodies, an ELISA was established. Briefly, wells of 96-well microtiter plates were coated with a solution containing 10 g/ml of the muc-1 peptide and 2% bovine serum albumin to reduce non-specific binding. 50 l of sera obtained from immunized mice were appropriately diluted and added to the wells. After incubating for 1 h at RT, sheep anti-mouse immunoglobulin conjugated to horseradish peroxidase (Amersham Life Science) was added and incubated at RT for an additional hour. The assays were subsequently developed by the addition of 50 l of 0.03% 2,2'-azinodi(3-ethylbenzthiazoline sulphonate (Sigma), 0.02% H 2 O 2 (Merck, Darmstadt, Germany) in 0.1 M citrate buffer, pH 4.25. The mixture was incubated for 20-30 min at RT until the desired intensity was achieved and the absorbance at 405 nm determined using a plate reader. Normal mouse serum (NMS) was employed as the negative control.
Measurement of IL-2 using CTLL-2 lines
5 × 10 5 spleen cells prepared separately from the immunized mice were cultured in the presence of 10 g/ml of the muc-1 peptide. After 48 h, the culture supernatant was collected and employed to set up the proliferation assays with the IL-2-dependent CTLL-2 cells. 5 × 10 peptide. Culture supernatants were collected following 3 days' incubation. For ELISA, 50 l of the culture supernatant was added to ELISA plates coated with 4 g/ml of rat anti-mouse IFN-␥ or rat anti-mouse IL-10 antibody (BD Pharmigen) and incubated at RT for 1 h. The plates were then washed with Tween-20-PBS and incubated at RT for 1 h with secondary biotinylated rat antibody against mouse IFN-␥ or mouse IL-10 (1 g/ml). After washing the plates, 50 l of avidin-peroxidase (Sigma Chemical) was added and incubated for 30 min at RT. The plates were further washed and then developed using the 2,2'-azino-di(3-ethylbenzthiazoline sulphonate substrate (Sigma Chemical). The absorbance at 405 nm was determined after incubation for 30 min at RT. Recombinant mouse IFN-␥ and mouse IL-10 were employed as standards to generate the standard curve.
Tumor protection assay
The ability of mice to retard tumor growth following in vivo stimulation with pNGVL3-hFLex plasmid DNA and 300 g muc-1 peptide were performed by challenging the immunized mice 10 days later with RMA-muc-1 tumor cells or parental untransfected RMA tumor cells. 
